Sun’s Teriparatide And Multiple Aubagio Rivals Among CHMP Recommendations
Accord Healthcare And Viatris’ Mylan Receive Nods For Generics
Sun’s rival to Forsteo, Accord and Mylan’s versions of Aubagio and Accord’s Nexavar generic were all endorsed by the European Medicines Agency at the CHMP’s September meeting.
You may also be interested in...
For just shy of $1bn, Halozyme Therapeutics is set to acquire drug development and injectable technology specialist Antares Pharma, providing it with a portfolio and pipeline of Teva products through a long-term partnership.
With multiple Humira biosimilars slated for launch in the US next year, some simultaneously, a Vizient survey provides some insights into what could be the most important differentiating aspects. Generics Bulletin speaks to Steven Lucio, Vizient senior principal of pharmacy solutions, about the findings.
Italian API and CDMO specialist Olon is expanding its high-potency capabilities at a site in India, at the same time as unveiling plans to invest a further €30m in a domestic biotech hub.